Literature DB >> 32432144

Liver cirrhosis in a child associated with Castleman's disease: A case report.

Soya Kobayashi1, Ayano Inui2, Tomoyuki Tsunoda1, Syuichiro Umetsu1, Tsuyoshi Sogo1, Masaaki Mori3, Masato Shinkai4, Tomoo Fujisawa1.   

Abstract

BACKGROUND: Castleman's disease (CD) is a lymphoproliferative disorder. TAFRO syndrome is classified as a variant of CD based on its key clinical manifestations of thrombocytopenia, anasarca (generalized edema and pleural effusion), fever (pyrexia), reticulin fibrosis in the bone marrow and the proliferation of megakaryocytes, and organomegaly (such as hepatosplenomegaly and multiple lymphadenopathies); TAFRO syndrome is mainly reported in Japanese patients. To our knowledge, this is the first pediatric case report detailing a CD-associated disorder progressing to cirrhosis. CASE
SUMMARY: A 10-year old male patient presented with fever and anemia. Six months before hospitalization, he had remarkable abdominal distention. Subsequently, he visited a clinic for a fever that lasted 5 d. The physical findings were marked hepatosplenomegaly and cervical lymphadenopathy. A blood test revealed leukocytosis, microcytic anemia, aspartate aminotransferase-dominant transaminase elevation, high levels of C-reactive protein, polyclonal hypergammaglobulinemia, and high levels of interleukin-6 and vascular endothelial growth factor. Abdominal contrast computed tomography and magnetic resonance imaging suggested cirrhosis, which was confirmed by liver histology. Histological findings in the enlarged hepatic lymph nodes revealed both hyperplasia and atrophy of lymphoid follicles with some vascular hyperplasia and moderate plasmacytosis between the lymphoid follicles, which is compatible with lymph node histology in TAFRO syndrome. Prednisolone was not effective in reducing the patient's symptoms; therefore, the patient was prescribed tocilizumab. To date, the patient remains free of fever and continues to receive tocilizumab.
CONCLUSION: We described the clinicopathological features of TAFRO syndrome to highlight the clinical presentation of this rare disease in a pediatric case. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Case report; Castleman disease; Child; Liver cirrhosis; Multi-centric Castleman’s disease; Tocilizumab

Year:  2020        PMID: 32432144      PMCID: PMC7211522          DOI: 10.12998/wjcc.v8.i9.1656

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


  25 in total

1.  HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease.

Authors:  T Suda; H Katano; G Delsol; C Kakiuchi; T Nakamura; M Shiota; T Sata; M Higashihara; S Mori
Journal:  Pathol Int       Date:  2001-09       Impact factor: 2.534

2.  Giant lymph node hyperplasia (Castleman's disease): a clinical study of eight patients.

Authors:  Y Baruch; Y Ben-Arie; H Kerner; M Lorber; L A Best; R Gershoni-Baruch
Journal:  Postgrad Med J       Date:  1991-04       Impact factor: 2.401

3.  Nodular regenerative hyperplasia of the liver and Castleman's disease: potential role of interleukin-6.

Authors:  Ayako Kiyuna; Takashi Sunagawa; Akira Hokama; Masato Touyama; Ryosaku Tomiyama; Hiroshi Sakugawa; Fukunori Kinjo; Atsushi Saito
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

Review 4.  A reference guide for management of Castleman disease.

Authors:  Kazuyuki Yoshizaki
Journal:  Rinsho Ketsueki       Date:  2017

5.  Hypoxia stimulates proximal tubular cell matrix production via a TGF-beta1-independent mechanism.

Authors:  C Orphanides; L G Fine; J T Norman
Journal:  Kidney Int       Date:  1997-09       Impact factor: 10.612

Review 6.  Systemic sclerosis: a prototypic multisystem fibrotic disorder.

Authors:  John Varga; David Abraham
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

7.  Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy.

Authors:  N Nishimoto; M Sasai; Y Shima; M Nakagawa; T Matsumoto; T Shirai; T Kishimoto; K Yoshizaki
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

Review 8.  TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review.

Authors:  Kazuya Sakai; Takeshi Maeda; Akira Kuriyama; Noriaki Shimada; Kenji Notohara; Yasunori Ueda
Journal:  Mod Rheumatol       Date:  2016-02-17       Impact factor: 3.023

Review 9.  HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

Authors:  David C Fajgenbaum; Frits van Rhee; Christopher S Nabel
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113

10.  Multicentric Castleman's disease with multiple hepatic mass lesions mimicking malignant liver tumors.

Authors:  Toshimitsu Ueki; Masaru Nasuno; Hiroko Kaiume; Yuki Hiroshima; Masahiko Sumi; Masahide Watanabe; Dai Inoue; Yasufumi Masaki; Yasuharu Sato; Masaru Kojima; Hikaru Kobayashi
Journal:  Rinsho Ketsueki       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.